Analyst Price Targets — AD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 11:42 am | — | RBC Capital | $52.00 | $52.52 | TheFly | Array Digital cut to Sector Perform at RBC on reduced organic growth view |
| March 9, 2026 11:36 am | Jonathan Atkin | RBC Capital | $54.00 | $49.06 | TheFly | Array Digital price target lowered to $54 from $60 at RBC Capital |
| February 23, 2026 2:46 pm | — | Raymond James | $53.00 | $49.30 | TheFly | Array Digital price target lowered to $53 from $63 at Raymond James |
| November 25, 2025 3:03 pm | Jonathan Atkin | RBC Capital | $56.00 | $47.14 | TheFly | Array Digital price target lowered to $56 from $62 at RBC Capital |
| October 27, 2025 9:31 am | — | RBC Capital | $62.00 | $49.90 | TheFly | Array Digital Infrastructure initiated with an Outperform at RBC Capital |
Latest News for AD
More than 75% of LeqembiÂ-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEAD
LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a
LEQEMBIÂ Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.